# Summit Therapeutics Inc. Common Stock (SMMT) — Stock CV

Summit Therapeutics Inc. is a $14.0B healthcare company. It holds more cash than debt.

> Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic.

## Identity

- **Ticker**: SMMT
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: MIAMI, FL
- **Employees**: 265
- **Website**: https://www.smmttx.com
- **Market cap**: $14.0B
- **Last price**: $17.55
- **Financial profile**: Strained

## Vitals (TTM)

- **Net income**: -$2.53B
- **Free cash flow**: -$932M
- **Net cash**: $670M

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 20 |
| Growth | 0 |
| Profitability | 0 |
| Health | 50 |
| Quality | 0 |
| Moat | 0 |

## Qualifications (beginner checklist) — 3 of 8 passed

- [ ] Profitable — -$2.53B TTM
- [x] Profit growing — +77.4% YoY
- [ ] Generates cash — -$932M TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $14.0B market cap
- [ ] Not printing shares — +40.4% shares over ~5y
- [ ] Proven track record — 0/7 profitable years
- [ ] Financially stable — health score 25/100

## Experience (career milestones)

- **Q2 2026** — 6 open-market insider purchases: ~7.9M shares bought by insiders
- **FY2023** — Became debt-free: cash now exceeds total debt

## Strengths

- Net cash position after subtracting debt from cash

## Watch-outs

- Not profitable — 9027.1% net margin
- Negative free cash flow (-$932.2M)
- Thin interest coverage (-121.3×)
- Loss-making in 6 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2022 | $2.15M | -$198M | -$148M |
| FY2023 | $0 | -$2.29B | -$190M |
| FY2024 | $0 | -$529M | -$329M |
| FY2025 | — | -$2.63B | -$735M |
| FY2026 | — | -$595M | -$387M |

---

Source: https://stockcv.com/SMMT — derived from company filings; may be delayed or incomplete. Information, not investment advice.